SCHEMBL973298

SCHEMBL973298

Cc1nc(C2CCCCC2)n2c1c(N)nc1ccc(OCC3CC3)cc12

nearest known ligand 0.43

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.43
PDE10A Q9Y233 4/20 0.43
PDE2A O00408 7/20 0.40
ALOX5AP P20292 4/20 0.39
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
PARP15 Q460N3 1/20 0.35
PARP10 Q53GL7 1/20 0.35
ACACB O00763 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL972747 0.92 PDE10A (0.51) IGF1RPDE10APDE2AALOX5APMAOA
SCHEMBL970074 0.86 PDE10A (0.52) PDE10APDE2AALOX5AP
SCHEMBL3661859 0.82 PDE10A (0.41) IGF1RPDE10APDE2AALOX5APMAOA
SCHEMBL973299 0.81 PDE2A (0.45) IGF1RPDE10APDE2AACACB
SCHEMBL971191 0.81 PDE2A (0.41) PDE10APDE2AACACB
SCHEMBL968377 0.80 PDE10A (0.46) PDE10APDE2A
SCHEMBL968810 0.77 PDE10A (0.62) PDE10APDE2AALOX5AP
SCHEMBL3659601 0.73 PDE10A (0.67) PDE10APDE2AALOX5AP
SCHEMBL970101 0.72 PDE10A (0.47) PDE10APDE2A
SCHEMBL972749 0.72 PDE2A (0.50) PDE10APDE2AACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2225248-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 Wyeth LLC (US) 2010-09-08 EP claimed
WO-2009070584-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 WYETH (US) 2009-06-04 WO claimed
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 ELBION GMBH (DE) 2009-06-04 US claimed
US-7875618-B2 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) WYETH (US) 2011-01-25 US disclosed
EP-2225248-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 Wyeth LLC (US) 2010-09-08 EP disclosed
WO-2009070584-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 WYETH (US) 2009-06-04 WO disclosed
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 ELBION GMBH (DE) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 PDE12, PDE5A, PDE10A IGF1R 2508/4885PDE10A 3/4885PDE2A 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.